Table 3.

Prescribing Patterns

Before-JNC 7 Cohort (n = 15,258)After-JNC 7 Cohort n = 4,000P
Number of agents (n [%])
    No drug therapy908 (6.7)249 (6.2)<.0001
    Monotherapy6196 (45.4)1365 (34.1)
    Dual therapy4283 (31.4)1425 (35.6)
    Triple+ therapy2251 (16.5)961 (24.0)
Class of agents used in patients receiving therapy (n [%])n = 14,350n = 3751
    Beta-blockers3739 (29.4)1340 (35.7)<.0001
    ACE inhibitors4248 (33.4)1229 (32.7)
    Calcium channel blockers3644 (28.6)967 (25.8)
    ARBs1033 (8.1)508 (13.5)<.0001
    Diuretics–total3950 (31.0)1522 (40.6)<.0001
        Thiazide889 (7.0)748 (19.9)<.0001
        Nonthiazide3061 (24.0)774 (20.6)
    Alpha-blockers708 (5.6)259 (6.9).0020
    Fixed-dose combination agents*1516 (11.9)783 (20.8)<.0001
  • * Fixed-dose combination agents included ACE inhibitor/calcium channel blocker, ACE inhibitor/diuretic, ARB/diuretic, beta-blocker/diuretic, or vasodilator/diuretic.

  • Includes patients’ prescribed antihypertensive therapy.

  • ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker.